URGN UroGen Pharma Ltd.: institutional ownership and insider trading
200 funds reported holding $1.59B of UroGen Pharma Ltd. in their latest 13F filings; in Q2 2026 funds net sold $147M, with 38 new positions and 21 funds selling out; over the last 12 months insiders bought $0 and sold $4.77M on the open market; over its last four quarters it reported revenue of $189M and net income of −$97.6M.
URGN revenue and earnings
- Quarter ended Jun 30, 2026: revenue $72.5M, net income −$14.4M
- Quarter ended Mar 31, 2026: revenue $51.0M, net income −$23.6M
- Quarter ended Dec 31, 2025: revenue $37.8M, net income −$26.4M
- Quarter ended Sep 30, 2025: revenue $27.5M, net income −$33.3M
Famous investors holding URGN
- D. E. Shaw (D. E. Shaw & Co.): $42.2M, 0.0% of the portfolio
- Cathie Wood (ARK Investment Management): $3.74M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $5.48M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $3.93M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $2.95M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $2.59M, 0.0% of the portfolio
Largest institutional holders of URGN
- RTW INVESTMENTS, LP — $167M
- BlackRock, Inc. (BLK) — $118M
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $94.8M
- Kynam Capital Management, LP — $89.6M
- Jefferies Financial Group Inc. (JEF) — $80.9M
- SG Americas Securities, LLC — $75.5M
- AMERICAN CENTURY COMPANIES INC — $62.0M
- ACORN CAPITAL ADVISORS, LLC — $61.6M
- Point72 Asset Management, L.P. — $56.1M
- FRONTIER CAPITAL MANAGEMENT CO LLC — $55.5M
Recent URGN insider trades
- Oct 8, 2026: Degnan Chris sold 2,202 shares ($80.8K)
- Sep 8, 2026: Smith Jason Drew sold 1,519 shares ($64.6K)
- Sep 8, 2026: Schoenberg Mark sold 871 shares ($37.4K)
- Aug 20, 2026: Schoenberg Mark sold 60,677 shares ($2.85M)
5%+ owners
- The Toronto-Dominion Bank: 6.7% (Schedule 13G/A, filed Aug 12, 2026)
- BlackRock, Inc.: 5.2% (Schedule 13G, filed Apr 27, 2026)
Who owns the most URGN stock?
The largest institutional holders of UroGen Pharma Ltd. in the latest 13F filings are RTW INVESTMENTS, LP ($167M), BlackRock, Inc. (BLK) ($118M), MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) ($94.8M).
Are insiders buying or selling URGN?
Over the last 12 months insiders bought $0 and sold $4.77M of UroGen Pharma Ltd. stock on the open market (SEC Form 4).
Which famous investors own URGN?
D. E. Shaw, Cathie Wood, Two Sigma, Izzy Englander, Ken Griffin.
What was URGN's revenue last quarter?
UroGen Pharma Ltd. reported revenue of $72.5M for the quarter ended June 30, 2026, with net income of −$14.4M.
Which ETFs hold URGN?
3 ETFs and mutual funds hold it among their top 100 positions, including ANOAX, QWVOX, AGCHX.